← All trials
NCT02454556
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2015
- Primary completion
- Dec 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 106
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Gema Biotech S.A.Lead sponsor
- QUID Quality in Drugs and Devices Latin American Consulting SRLCollaborator
- Halitus Instituto MedicoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.